New European Society of Cardiology/European Atherosclerosis Society Guideline for the Management of Dyslipidemia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The management of dyslipidemia is one of the crucial components in the prevention of atherosclerotic cardiovascular disease. Recently, the task force for the management of dyslipidemias of the ESC (European Society of Cardiology) and the EAS (European Atherosclerosis Society) updated their clinical guideline for the first time in 5 years. Although the new guideline maintained the previous recommendations in almost every aspect, there were some updates and modifications in the risk categorization and therapeutic modalities. In this review, I'd like to summarize the updated recommendations and differences compared to the previous version.
Abstract
The management of dyslipidemia is one of the crucial components in the prevention of atherosclerotic cardiovascular disease. Recently, the task force for the management of dyslipidemias of the ESC (European Society of Cardiology) and the EAS (European Atherosclerosis Society) updated their clinical guideline for the first time in 5 years. Although the new guideline maintained the previous recommendations in almost every aspect, there were some updates and modifications in the risk categorization and therapeutic modalities. In this review, I'd like to summarize the updated recommendations and differences compared to the previous version.
참고문헌 (19)
- European Association for Cardiovascular Prevention &Rehabilitation, "ESC", EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), 2011, pp.32, 1769~1818
- Catapano AL, "2016 ESC", EAS Guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, Circulation, pp.2014, 129[DOI]
- Ridker PM, "Statins: new American guidelines for prevention of cardiovascular disease", Lancet, 382, pp.1762~1765 (2013)
- Pencina MJ, "Application of new cholesterol guidelines to a population-based sample", N Engl J Med, 370, pp.1422~1431 (2014)
- HPS2-THRIVE Collaborative Group, "Effects of extended-release niacin with laropiprant in high-risk patients", N Engl J Med, 371, pp.203~212 (2014)
- AIM-HIGH Investigators, "Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy", N Engl J Med, 365, pp.2255~2267 (2011)
- SEC Working Group for the 2016 ESC Guidelines for the Management of Dyslipidemias 2016, "Comments on the 2016 ESC", EAS Guidelines for the management of dyslipidemias, 2017, pp.70, 72~77
- Cholesterol Treatment Trialists’ (CTT) Collaboration, "Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
- Preiss D, "Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a metaanalysis", JAMA, 305, pp.2556~2564 (2011)
- Waters DD, "Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes", J Am Coll Cardiol, 61, pp.148~152 (2013)
- Cannon CP, "Ezetimibe added to statin therapy after acute coronary syndromes", N Engl J Med, 372, pp.2387~2397 (2015)
- Sabatine MS, "Efficacy and safety of evolocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1500~1509 (2015)
- Robinson JG, "Efficacy and safety of alirocumab in reducing lipids and cardiovascular events", N Engl J Med, 372, pp.1489~1499 (2015)
- Barter PJ, "Effects of torcetrapib in patients at high risk for coronary events", N Engl J Med, 357, pp.2109~2122 (2007)
- Lincoff AM, "Evacetrapib and cardiovascular outcomes in high-risk vascular disease", N Engl J Med, 376, pp.1933~1942 (2017)
- Schwartz GG, "Effects of dalcetrapib in patients with a recent acute coronary syndrome", N Engl J Med, 367, pp.2089~2099 (2012)
- Landray MJ, "Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL): a large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease:trial design, recruitment, and baseline characteristics", Am Heart J, 187, pp.182~190 (2017)
- Tonelli M, "Lipid management in chronic kidney disease:synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline", Ann Intern Med, 160, pp.182~ (2014)